1. Allen, M., Millett, P., Dawes, E. and Rushton, N. (1994): Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro. Clin. Mater., 16, 189-194.
2. Boxwell, D., Haverkos, H., Kukich, S., Struble, K. and Jolson, H. (2001): Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--Worldwide, 1997-2000. MMWR, 49, 1153-1156.
3. Calmy, A., Hirschel, B., Cooper, D.A. and Carr, A. (2009): A new era of antiretroviral drug toxicity. Antivir. Ther., 14, 165-179.
4. Clotet, B. (2008): Once-daily dosing of nevirapine in HAART. J. Antimicrob. Chemother., 61, 13-16.
5. Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., Lauritsch, I., Müller, E., Pascolo, E., Sauter, G., Pantic, M., Martens, U.M., Wenz, C., Lingner, J., Kraut, N., Rettig, W.J. and Schnapp, A. (2001): A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J., 20, 6958-6968.